(Q46520115)

22 December 2017

title

Low skeletal muscle is associated with toxicity in patients included in phase I trials (English)

1 reference

22 December 2017

main subject

phase I clinical trial

0 references

author

Vickie E. Baracos

6

1 reference

22 December 2017

Olivier Mir

object named as

O Mir

4

0 references

author name string

Sophie Cousin

1

1 reference

22 December 2017

A Hollebecque

2

1 reference

22 December 2017

S Koscielny

3

1 reference

22 December 2017

A Varga

5

1 reference

22 December 2017

J C Soria

7

1 reference

22 December 2017

S Antoun

8

1 reference

22 December 2017

publication date

17 December 2013

1 reference

22 December 2017

Investigational New Drugs

published in

1 reference

22 December 2017

volume

32

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

page(s)

382-387

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1007/s10637-013-0053-6

exact match

0 references

cites work

Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Relationships between body composition parameters and fluorouracil pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Relationships among liver and kidney volumes, lean body mass and drug clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Lean body mass as a predictor of drug dosage. Implications for drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Candidate mechanisms underlying effects of contractile activity on muscle morphology and energetics in cancer cachexia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0053-6

Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24343673

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-013-0053-6

1 reference

22 December 2017

1 reference

22 December 2017